Front. Neurosci. Frontiers in Neuroscience Front. Neurosci. 1662-453X Frontiers Media S.A. 10.3389/fnins.2017.00498 Neuroscience Mini Review Neurophysiology of the “Celiac Brain”: Disentangling Gut-Brain Connections Pennisi Manuela 1 Bramanti Alessia 2 Cantone Mariagiovanna 3 Pennisi Giovanni 4 Bella Rita 5 Lanza Giuseppe 3 * 1Spinal Unit, Ospedale Cannizzaro Catania, Italy 2Centro Neurolesi Bonino Pulejo (IRCCS) Messina, Italy 3Department of Neurology IC, Oasi Maria SS (IRCCS) Troina, Italy 4Department of Surgery and Medical-Surgical Specialties, University of Catania Catania, Italy 5Section of Neurosciences, Department of Medical and Surgical Sciences and Advanced Technology, University of Catania Catania, Italy

Edited by: Benjamin Boutrel, University of Lausanne, Switzerland

Reviewed by: Clara Rossetti-Marcon, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland; Kshitij Jadhav, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland

*Correspondence: Giuseppe Lanza glanza@oasi.en.it

This article was submitted to Neuroenergetics, Nutrition and Brain Health, a section of the journal Frontiers in Neuroscience

 05 09 2017 2017 11 498 28 06 2017 23 08 2017 Copyright © 2017 Pennisi, Bramanti, Cantone, Pennisi, Bella and Lanza. 2017 Pennisi, Bramanti, Cantone, Pennisi, Bella and Lanza

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Celiac disease (CD) can be considered a complex multi-organ disorder with highly variable extra-intestinal, including neurological, involvement. Cerebellar ataxia, peripheral neuropathy, seizures, headache, cognitive impairment, and neuropsychiatric diseases are complications frequently reported. These manifestations may be present at the onset of the typical disease or become clinically evident during its course. However, CD subjects with subclinical neurological involvement have also been described, as well as patients with clear central and/or peripheral nervous system and intestinal histopathological disease features in the absence of typical CD manifestations. Based on these considerations, a sensitive and specific diagnostic method that is able to detect early disease process, progression, and complications is desirable. In this context, neurophysiological techniques play a crucial role in the non-invasive assessment of central nervous system (CNS) excitability and conductivity. Moreover, some of these tools are known for their valuable role in early diagnosis and follow-up of several neurological diseases or systemic disorders, such as CD with nervous system involvement, even at the subclinical level. This review provides an up-to-date summary of the neurophysiological basis of CD using electroencephalography (EEG), multimodal evoked potentials, and transcranial magnetic stimulation (TMS). The evidence examined here seems to converge on an overall profile of “hyperexcitable celiac brain,” which partially recovers after institution of a gluten-free diet (GFD). The main translational correlate is that in case of subclinical neurological involvement or overt unexplained symptoms, neurophysiology could contribute to the diagnosis, assessment, and monitoring of a potentially underlying CD.

 celiac disease cortical excitability electroencephalography evoked potentials transcranial magnetic stimulation neuroplasticity Introduction

Celiac disease (CD) is an autoimmune disorder triggered by the ingestion of gluten that, in genetically predisposed individuals, leads to damage of the small intestine and consequent malabsorption. Most patients (95% of them) are carriers of the DQ2 or DQ8 haplotype of the histocompatibility complex class II human leukocyte antigen (Lebwohl et al., 2017). Tissue transglutaminase (tTG) is the main auto-antigen (Alaedini and Green, 2008), whereas gut histopathology shows variable degrees of small bowel mucosal villi atrophy. CD affects 0.3–1.5% of the general population (approximately 1 of 120–300 people in Europe and America) (Morello et al., 2003; Bingley et al., 2004). To date, the only established therapy is a lifetime dietary gluten restriction, which is usually followed by relief of several clinical manifestations, normalization of histological and serological markers, as well as decreased risk of associated malignant and non-malignant complications (Holmes, 1996, 2002).

Clinically, although diarrhea and other gastro-intestinal symptoms can commonly be observed at disease onset or in its early phases in both pediatric patients and young adults, they are not as frequent as in the past (Campagna et al., 2017). Many adults (>50%) exhibit significant extra-intestinal involvement even without typical CD manifestations (Cooke and Smith, 1966; Hadjivassiliou et al., 2002a, 2010, 2014; Bushara, 2005; Uygur-Bayramicli and Ozel, 2011; Castillo et al., 2015). Therefore, CD is considered a complex systemic disorder with multifactorial pathogenesis that should be investigated from genetic, biological, and environmental perspectives.

Currently, little is known about the neurophysiology of central nervous system (CNS) damage in CD. This review aims to summarize the electrophysiological evidence on CNS functioning and pathology, including the clinical and instrumental response to a gluten-free diet (GFD).

 Neurological complications of celiac disease: a brief overview

Nowadays, it is widely accepted that the typical disease represents a small proportion of the so-called “CD iceberg,” because 5–6 fold more patients present with atypical or silent forms (Green et al., 2005). Neurological manifestations may either precede or follow the disease, or be present at its onset (Hadjivassiliou et al., 2002a, 2010, 2014; Briani et al., 2008). Therefore, a sensitive and specific diagnostic method able to recognize early disease process, progression, and complication would be desirable.

To date, both the causative factors and pathophysiological mechanisms of neurological involvement in CD remain a matter of debate. According to the literature, the nervous system may be one of the elective sites of gluten-mediated pathogenesis, including cross-reacting antibodies, immune-complex deposition, direct neurotoxicity, other immune-mediated factors, and deficiency of vitamin and other nutrients secondary to chronic malabsorption (Zelnik et al., 2004; Bushara, 2005; Abenavoli, 2010; Parisi et al., 2015). Recently, studies using single photon emission computed tomography showed regional changes in cerebral perfusion, with regression after institution of a GFD (De Santis et al., 1997; Usai et al., 2004). The authors argued that the cerebral hypoperfusion might be related to intestinal hyperemia from immune-mediated or endothelial damage due to immune-complex deposition likely involving antibodies against gliadin (De Santis et al., 1997). Alternatively, cortical brain hypoperfusion could reflect focal vasculitis secondary to perivascular inflammation (Usai et al., 2004).

Cerebellar ataxia

“Gluten ataxia” is one of the first recognized symptoms (Cooke and Smith, 1966) and the most frequent neurological disturbance in CD (Hadjivassiliou et al., 2015). Dysarthria, cortical-spinal signs, eye and gaze movement disorders, and cerebellar ataxia are representative presentations. Recent studies showed deposits of antibodies against tTG on cerebellar blood vessels, adding support to a blood-brain barrier (BBB) dysfunction in CD (Hadjivassiliou et al., 2006, 2015). Interestingly, gluten ataxia is not usually related to intestinal manifestations or vitamin deficiency, and improvement with a GFD is possible (Hadjivassiliou et al., 2006).

 Peripheral neuropathy

Peripheral neuropathy is the second most common neurological manifestation of CD (up to half of patients) after cerebellar ataxia, and can appear even before diagnosis (Chin et al., 2003; Chin and Latov, 2005). Studies on the effect of a GFD on peripheral neuropathy are conflicting, with some authors reporting clinical improvement whereas others concluding a lack of relevant response (Luostarinen et al., 2003; Siqueira Neto et al., 2004). A previous study on 32 consecutive adult patients complaining of peripheral neuropathy, autonomic dysfunction, or both, and showing anti-neuronal antibodies found no response despite the adoption of a GFD (Tursi et al., 2006).

 Epilepsy

A bidirectional link between epilepsy and CD has been established in several studies, although not all (Vieira et al., 2013), with rates of prevalence from 3.5 to 7.2% (Cooke and Smith, 1966; Zelnik et al., 2004; Bushara, 2005; Uygur-Bayramicli and Ozel, 2011; Hadjivassiliou et al., 2014; Parisi et al., 2015). A large population-based cohort study observed an increased risk of CD in subjects of all ages, including children, even when epilepsy was independently restricted to patients receiving the diagnosis of epilepsy and those with prescriptions of antiepileptic drugs (Ludvigsson et al., 2012). The hypotheses accounting for epilepsy in CD included a gluten-mediated toxicity, an immune-induced cortical damage, the presence of cerebral calcifications, and vitamins/trace elements malabsorption. GFD usually controls seizures refractory to antiepileptic drugs (Hadjivassiliou et al., 2002a; Canales et al., 2006). CD-related progressive ataxia is associated with stimulus-sensitive myoclonus, opsoclonus-myoclonus, and sometimes with seizures (Borg, 2006; Deconinck et al., 2006).

 Headache

It has been reported that a GFD results in complaints of less severe headache symptoms by celiac patients (Hadjivassiliou et al., 2001). Accordingly, structural and functional neuroimaging studies were in favor of an association between migraine and CD, with relief after gluten restriction (Hadjivassiliou et al., 2001). However, when headaches in CD patients were compared with those in the general population, a conclusive association was not proven (Nikpour, 2012).

 Cognitive impairment and dementia

Adult CD patients often complain of mild cognitive symptoms called “brain fog,” which improves when gluten-restriction is started, but re-appears with dietary contamination (Lichtwark et al., 2014; Yelland, 2017). Concentration and attention difficulties, episodic memory deficits, word-retrieval problems, reduced mental acuity, and episodes of confusion or disorientation are the commonly reported features (Lurie et al., 2008). In some severely affected patients, dementia can develop as acalculia, confusion, amnesia, and personality disorders (Collin et al., 1991; Hu et al., 2006; Lurie et al., 2008; Casella et al., 2012). Despite long-term administration of a GFD, patients older than 65 years exhibited worse cognitive performance than age- and sex-matched controls (Casella et al., 2012).

 Neuropsychiatric disorders

Several psychiatric symptoms, including depression, bipolar disorder, apathy (Carta et al., 2003, 2015; Cicarelli et al., 2003), excessive anxiety (Bushara, 2005; Campagna et al., 2017), irritability (Hernanz and Polanco, 1991), schizophrenia (De Santis et al., 1997; Bushara, 2005), eating disorders (Addolorato et al., 2001), attention-deficit/hyperactivity disorder (Karwautz et al., 2008), autism (Niederhofer and Pittschieler, 2006), and sleep complaints (Barcia et al., 2008) have been associated with CD.

Reactive anxiety that usually ameliorates with a GFD is the predominant form of anxiety disorder in these patients. Depressive disturbances, which affect a relevant number of subjects, may significantly impair quality of life, and are a good predictor of lack of dietary compliance (Zingone et al., 2010). Therefore, screening patients for depression is of pivotal importance both at diagnosis and follow-up in order to advice psychological support and/or pharmacological therapy. Possible causative factors of mood disorders might be tryptophan deficiency secondary to chronic malabsorption (Hallert et al., 1982; Hernanz and Polanco, 1991) or co-morbidity with thyroid disease (Carta et al., 2002). Decreases in levels of serotonin, dopamine, and noradrenaline metabolites in cerebrospinal fluid as well as tryptophan and other monoamine precursors in serum were observed in untreated patients (Hallert et al., 1982; Hernanz and Polanco, 1991).

Clinical improvement was reported only after long-term administration of a GFD (>5 years) (van Hees et al., 2013), highlighting the importance of prolonged alimentary restriction on extra-intestinal CD symptoms as well.

 Neurophysiological techniques used to probe CNS involvement in celiac disease Electroencephalography

The spectrum of electroencephalography (EEG) features associated with CD is rather wide, although focal activity in terms of unilateral or bilateral spike or slow waves, mainly localized in the occipital regions, have been reported in most of the wakefulness EEG studies (Magaudda et al., 1993; Labate et al., 2001; Pratesi et al., 2003; Ranua et al., 2005; Lionetti et al., 2010; Licchetta et al., 2011; Aksoy et al., 2016). However, as recommended (Parisi et al., 2014), EEG patterns should not be considered disease-specific.

A recent prospective study among 307 CD children compared with 197 age- and sex-matched controls observed that patients were more prone to epileptiform activities on EEG (spike/sharp-wave discharges, especially in the occipital lobes but also in the central-temporal sites and in diffuse distribution). However, early and strict adherence to a GFD effectively decreased these findings (Işıkay et al., 2015a). In addition, a positive correlation between tTG level and epileptiform changes during sleep and awake EEG was found (Işıkay et al., 2015a). The concept that the occipital region is frequently involved in CD seems to be supported by the evidence of occipital calcium deposition, occipital lobe semiology, and EEG findings. The preferential involvement of this lobe may lie on several factors, such as its vulnerability to some metabolic circumstances (e.g., hypoglycemia and hypoxia) and its thinner morphological structure than other cortical regions (Işıkay et al., 2015b). However, the opposite scenario (the occurrence of CD in patients with “posterior” epileptic semiology) is not always true because in a group of 90 pediatric epileptic patients with occipital EEG abnormalities, tTG antibody was positive in only two (Canales et al., 2006).

CD-associated epilepsy has also been reported in association with other neurological signs, such as ataxia, tremor, and progressive myoclonus (Javed et al., 2012; Sarrigiannis et al., 2014). In these cases, epilepsy was usually refractory, and EEG demonstrated spike and waves in the right anterior and mid-temporal lobes, as well as bilateral slow and sharp waves. Some of these spike waves were present in association with localized jerks of the upper or lower limb, although without periodic complexes (Javed et al., 2012; Sarrigiannis et al., 2014). Finally, the fixation-off sensitivity phenomenon could be observed (Casciato et al., 2015).

In regard to the impact of dietary restriction, a recent study in 19 children with biopsy-proven CD revealed abnormal EEG findings in 48% of them that were no longer evident in most of the patients after 6 months of GFD (Parisi et al., 2015). However, some asymptomatic children and adolescents still manifested hyperexcitability to EEG despite the diet (Parisi et al., 2015).

In summary, CD screening should be performed in patients with cryptogenic and/or refractory epilepsy, or in the presence of unexplained EEG findings. Gluten restriction is usually effective in ameliorating the clinical-instrumental correlates.

 Evoked potentials

Few studies, most of which used somatosensory evoked potentials (SEPs), have explored CD with evoked potentials. Di Lazzaro and co-workers reported a patient whose lower limb SEPs presented enlargement of lumbar waves and bilateral lack of cortical responses, suggesting an impaired somatosensory conduction along the spinal dorsal columns; GFD induced complete clinical-instrumental recovery (Di Lazzaro et al., 2010). Another case presented one child with prolonged central conduction time among 27 treated children (Cakir et al., 2007). In patients with cerebellar ataxia associated with subclinical CD responding to a GFD, normal SEPs were reported (Pellecchia et al., 1999). However, in a large cohort of adult ataxic patients, more than half had loss or delayed P40 cortical response, suggesting dorsal column degeneration (Bürk et al., 2001). In regard to SEPs in cortical mycolonus, a previous study in two CD-proven subjects with myoclonic ataxic syndrome showed giant and time-locked cortical responses that preceded the myoclonus (Tijssen et al., 2000). The authors speculated that, in spite of the neurophysiological evidence of cerebral cortical involvement, the hyperexcitability was mainly located in the cerebellum, and that the effects on sensory-motor cortex represented a remote influence from cerebellar dysfunction (Tijssen et al., 2000). Conversely, the cortical electrophysiological origin of the myoclonus was argued by other researchers who found their patients responded poorly to a GFD and worsened progressively (Lu et al., 1986; Tison et al., 1989; Bhatia et al., 1995).

Although CD may impact the auditory system (Bürk et al., 2001), brainstem auditory evoked potentials (BAEPs) and vestibular evoked myogenic potentials were reported to be normal (Pawlak-Osińska et al., 2007). More recently, it was found that only 1 of 25 patients had abnormalities in BAEPs in terms of moderate sensorineural hearing loss (Aksoy et al., 2016).

Complications affecting visual pathways may develop in CD and be evidenced by visual evoked potentials (VEPs) (Bürk et al., 2001; Freeman, 2008; Hadjivassiliou et al., 2010). In particular, patients can show abnormalities on VEPs without evident lesions at neuroimaging (Aksoy et al., 2016). A previous case described a slight increase of P100 wave latency bilaterally at pattern-reversal VEPs that reverted back to normal after a GFD (Pellecchia et al., 1999). Given their role in detecting even preclinical pathology in subjects with normal ophthalmological and brain imaging exams, VEPs may provide useful insights in neurologically asymptomatic CD patients (Aksoy et al., 2016).

 Transcranial magnetic stimulation

In 1999, Pellecchia and co-workers first reported motor evoked responses to transcranial magnetic stimulation (TMS) in a CD patient who exhibited reduced amplitude in the rectus femoris muscle that improved with diet; however, motor responses remained undetectable in the tibialis anterior muscle (Pellecchia et al., 1999). A year later, report of delayed motor response in the left tibialis anterior muscle and abnormal cortical inhibition was published in one of three CD patients with cortical myoclonus (Tijssen et al., 2000).

Specific TMS studies before and after GFD were published more recently. TMS is an electrophysiological tool able to non-invasively explore the excitation state of motor cortical areas and conductivity of the pyramidal tract in vivo. Moreover, it is capable of unveiling subclinical central motor involvement in different neurological and psychiatric diseases or systemic disorders affecting the CNS (Bella et al., 2011a,b, 2016; Pennisi et al., 2011a,b, 2015, 2017; Concerto et al., 2013; Lanza et al., 2013, 2015a,b, 2017a,b; Cantone et al., 2014, 2017), also providing prognostic (Bella et al., 2013; Pennisi et al., 2016) and therapeutic implications (Spampinato et al., 2013; Concerto et al., 2015; Bordet et al., 2017). Lastly, the so-called “pharmaco-TMS” can selectively probe the functioning of different central neurotransmission pathways, such as glutamate, gamma-aminobutyric-acid (GABA), monoamine, and acetylcholine, by testing their pharmacological agonists or antagonists (Paulus et al., 2008; Ziemann et al., 2015).

The first TMS study investigated 20 de novo CD patients without apparent neurological involvement and 20 age-matched controls (Pennisi et al., 2014). TMS revealed cortical motor disinhibition and hyperfacilitation, which is a profile compatible with dysfunctional GABAergic and glutamatergic transmissions, in patients. The authors hypothesized that an imbalance of excitatory and inhibitory circuits within the motor cortex might be the neurochemical correlate of the cross-interaction between antibodies against gliadin and specific neuronal antigens. An alternative explanation was the deposition of tTG-immunoglobulin leading to an abnormal ion levels across neuronal membrane. Likewise, antibodies synthesized within the CNS and directed against glutamic acid decarboxylase might disrupt the functioning of GABAergic interneurons (Pennisi et al., 2014).

The same cohort of patients underwent re-evaluation after a relatively short time of a GFD (median of 16 months) (Bella et al., 2015). Their gastrointestinal symptoms were ameliorated but, unexpectedly, the cortical excitability to TMS further increased. This finding was hypothesized to represent a plastic re-organization of the cerebral cortex triggered by gluten exposure and independent of GFD. On the other hand, diet duration or compliance might not have been enough to induce an adequate remission (Bella et al., 2015). A recent cross-sectional TMS study after a much longer GFD (mean period of 8.35 years) showed that a more prolonged period of gluten restriction was required to revert the cortical changes in adult CD patients. Nevertheless, regardless of diet, some specific excitatory features to TMS remained, probably suggesting an intracortical synaptic rearrangement, mostly involving glutamate-mediated interneurons (Pennisi et al., 2017).

 Discussion

The main translational value of this review is that clinical neurophysiology can contribute to the diagnosis, assessment, and monitoring of CD even in patients with subclinical CNS involvement or unexplained neurological symptoms (Table 1, Figure 1). In particular, the majority of electrophysiological changes are often subclinical (“celiac iceberg”), and these need to be strictly monitored because of the possibility of progression to clinically visible neurological syndrome in both young and adult patients (“symptomatic celiac disease”). Accordingly, it has been shown that there is an increased risk of neurological complications in atypical or silent CD forms, especially in older patients or those older at diagnosis (Aksoy et al., 2016). It is worth noting that, despite their valuable role, anti-ganglioside antibodies and neuronal antigens are not always specifically linked to the neurological manifestations and their progression in the course of CD (Kaplan et al., 1988; Gobbi et al., 1992; Hadjivassiliou et al., 1998, 2002b; Aksoy et al., 2016).

Studies using electrophysiological techniques probing the central nervous system involvement in patients with celiac disease.

Study Number of patients Sex Age (years) Neurological features Neurophysiology Main results Response to GFD Translational value
Lu et al., 1986 2 M/F M: 42/F: 54 Action limbs myoclonus, seizures, ataxia a) EEGb) SEPs a) M: bilateral high-amplitude spike and polyspike discharges; F: normalb) M: cortical responses greatly enlarged that preceded spontaneous muscle jerks, consistent with cortical reflex myoclonus; F: enlarged response on contralateral sensory-motor area No response First evidence of electrocortical pathology in CD
Tison et al., 1989 1 F 56 Arm, neck, face stimulus-sensitive and palatal myoclonus, cerebellar ataxia a) EEG (back averaging)b) SEPsc) VEPsd) BAEPs a) Cortical contralateral spike slow waves preceding myoclonusb) Increased P1-N2 amplitude responsec) Normald) Normal No response Myoclonus as a prominent feature of CD encephalopathy
Magaudda et al., 1993 8 5 F/3 M Mean 17.5 (range 10-23) Epilepsy EEG Spike and spike-waves in one or both parietal-occipital regions Seizures disappeared in 1 patient; 2 patients did not respond. Other data not reported Electrophysiological finding of hyperexcitable posterior cerebral regions in CD
Bhatia et al., 1995 4 1 F/3 M Mean 57.5 (range 44-68) Progressive myoclonic ataxic syndrome a) EEG (back averaging)b) SEPs a) Cortical reflex and/or action myoclonusb) Enlarged cortical SEPs Clinical progression despite strict diet Although the myoclonus was cortical, the electrophysiological origin was in the cerebellum
Mumford et al., 1996 1 M 44 Myoclonic ataxia, seizures EEG Frequent runs of bilateral High-voltage delta wave activity No response Patients with progressive ataxia and myoclonus should have a biopsy for CD
Pellecchia et al., 1999 1 M 34 Progressive cerebellar ataxia a) TMSb) VEPsc) SEPs a) Reduced amplitude of motor responsesb) Bilateral increase of P100 latencyc) Normal VEPs returned to normal after 2 years diet; partial response of TMS Impairment of central visual and motor pathways in CD
Tijssen et al., 2000 2 M 50 Myoclonic ataxic syndrome a) SEPsb) EEG (back averaging)c) TMS (1 patient) a) Enlarged cortical SEPsb) Time-locked cortical potential preceding the action myoclonusc) Delayed response in the left tibialis anterior and abnormal cortical inhibition Not reported The enhanced excitability of sensory-motor cortex may arise as a remote effect of cerebellar pathology in CD
Fung et al., 2000 1 F 48 Unilateral limb tremor, dystonia, myoclonus, and ataxia a) EEGb) SEPs (median nerve)e)c) Jerk-locked back averaging a) Normalb) Giant cortical response following stimulation of the affected sidec) No preceding cortical potential Not reported CD should be considered in patients with unexplained movement disorders and seizures
Hanagasi et al., 2001 1 F 31 Ataxia, stimulus-induced myoclonus, eye movement abnormalities a) EEGb) BAEPsc) SEPs (tibial nerve) a) Normalb) Normalc) Normal Myoclonus responded well to the diet CD as a cause of neurologic syndrome even without gastrointestinal symptoms
Bürk et al., 2001 12 7 F/5 M Mean 55 (range 30-76) Progressive cerebellar ataxia a) BAEPs (10 patients)b) VEPs (10 patients)c) SEPs a) Abnormal BAEPs in 10%b) Abnormal VEPs in 30%c) Loss or delayed P40 response in 58.3% Not reported Evidence of dorsal column degeneration; less frequent involvement of central visual pathway
Pratesi et al., 2003 1 M 3 Drug-resistant epilepsy EEG Slow background activity intermixed with frequent sharp and slow wave complexes Progressive seizure control Association between CD and refractory epilepsy
Cakir et al., 2007 27 18 F/9 M Mean 11.22 ± 4.27 (SD) Asymptomatic; isolated seizure in 3 a) EEGb) SEPs a) Normalb) Prolonged latencies in 3.7% Subclinical neurological changes more common in non-compliant patients Subclinical neurological abnormalities are frequent in pediatric CD
Pawlak-Osińska et al., 2007 30 Not reported Mean: 9.2 (range 6-18) Gaze and optokinetic nystagmus in most of them a) BAEPsb) VEMPs a) Normalb) Normal No response Neurological signs correlated with the histopathological changes
Briani et al., 2008 71 16 M/55 F Mean 36.7 ± 12.1 (SD) Headache, depression, peripheral neuropathy, epilepsy (16 patients) EEG Not reported No serological or electrophysiology change No clear correlation between anti-neural reactivity and neurologic dysfunction
Sallem et al., 2009 1 F 46 Generalized seizures, myoclonus, and ataxia EEG (sleep and wake) Occasional generalized poly-spike wave complexes No improvement CD as a differential diagnosis of myoclonic ataxia and progressive cerebellar dysfunction
Di Lazzaro et al., 2010 1 M 66 Fatigability, painful cramps and mild weakness at left lower limb SEPs (tibial nerve) Cortical responses bilaterally absent Clinical remission and improvement of SEPs Evidence of dorsal column involvement. Neurological symptoms even in older CD patients
Licchetta et al., 2011 8 7 F/1 M Mean 25.6 ± 4.85 (SD) Progressive myoclonic epilepsy EEG (inter-ictal) and video-EEG monitoring Focal posterior or diffuse spike-wave discharges; poly-spike-wave complexes 5 out of 7 patients did not respond CD as a cause of progressive myoclonic epilepsy. Peculiar involvement of the occipital lobe in CD
Javed et al., 2012 1 F 63 Late onset epilepsy, ataxia, tremor, progressive myoclonus a) EEGb) SEPs (tibial nerve) a) Right anterior and mid-temporal spike and waves, bilateral slow waves and sharp wavesb) Giant cortical SEPs No improvement Refractory CD is linked to progressive neurological syndrome
Parisi et al., 2014 2 (siblings) M/F M: 5/F: 4 M: seizures F: iron deficiency and poor growth Awake and sleep EEG M: left temporal spike and wave discharges, generalized abnormal activity F: bursts of bilateral occipital spikes and diffuse polyspikes and sharp waves No improvement A long follow-up may be required to clarify the relationships between clinical and EEG features
Sarrigiannis et al., 2014 9 3 F/6 M Mean 59.4 ± 10.4 (SD) Asymmetrical irregular myoclonus at limbs and sometimes face; “Jacksonian march” (3 patients) and secondarily generalized seizure (5 patients) a) Standard EEGb) SEPsc) Jerk-locked back averagingd) Long loop reflexes a) PLEDs, theta and delta activity (2 patients)b) Giant SEPs (5 patients)c) Cortical myoclonusd) Altered long-loop reflexes (5 patients) Ataxia and enteropathy improved, but myoclonus remained the most disabling feature The clinical involvement in CD covers the whole spectrum of cortical myoclonus
Casciato et al., 2015 10 9 F/1 M Mean 31.5 (range 18-44) Seizures EEG Slow and epileptiform abnormalities over parietal-occipital and temporal regions Decrease of seizure frequency in half of patients “Posterior” ictal semiology, EEG patterns and drug-resistance were peculiar features in CD
Pennisi et al., 2014 20 16 F/4 M Median 33.0 (range 24-45) Dysthymic disorder (5 patients); anxiety (2 patients) a) EEGb) TMS a) Normalb) Shorter CSP, reduced ICI, enhanced ICF GFD was not started yet (de novo patients) Disinhibition and hyperfacilitation of the motor cortex. Immune system dysregulation might trigger changes of cortical excitability
Dai et al., 2014 2 1 F/1 M M: 3 / F: 10 Tonic-clonic seizures and mild intellectual disability EEG Bilateral spikes and slow wave complexes in the occipital lobes, predominantly in the right hemisphere Not reported CD is more common among patients with occipital lobe epilepsy (often drug-resistant)
Işıkay et al., 2015a a) 216 (newly diagnosed CD group);b) 91 (GFD group 180 F/127 M a) Mean 10.15 ± 3.7 (SD)b) Mean 9.88 ± 4.2 (SD) Headache in 2.9% EEG Epileptiform activity (spike/sharp-wave discharges) in 24 patients; among them, 21 (9.7%) were in newly diagnosed group and 3 (3.3%) in GFD group Early strict GFD is advised in patients with epileptiform activities CD patients are prone to epileptiform activities
Işıkay et al., 2015b a) 43 (newly diagnosed CD group)b) 132 (formerly diagnosed group) 103 F/72 M Mean 10.6 ± 3.8 (SD) Headache in 31.4% EEG Epileptiform activity in 9.3% of newly diagnosed CD patients and in 1.5% of formerly diagnosed patients Decrease of EEG epileptiform discharges Increased epileptiform activity among newly-diagnosed patients; tissue transglutaminase correlated with EEG
Parisi et al., 2015 19 16 F/3 M Mean 9.82 ± 4.09 (SD) Headache in 36.8%; positive OSA score in 31.6% EEG Focal or generalized sharps and/or spikes and spike-waves in 48% of children Headache disappeared in 72% and EEG abnormalities in 78%; negative OSA score in all Consider atypical or silent CD in case of unexplained symptoms, sleep breathing disorder or EEG abnormalities
Bella et al., 2015 13 10 F/3 M 39 (range 24-46) Dysthymic disorder (1 patient) TMS Compared to the baseline (de novo):- decrease of median rMT- shorter CSP- reduced ICI- enhanced ICF Increased cortical excitability after a relatively short period of diet Functional cortical reorganization probably compensating for disease progression
Aksoy et al., 2016 65 26 M/39 F Mean 12.85 ± 4.23 (SD) Intellectual disability (3 patient); ophtalmoplegia and distonia (1 patient) a) EEGb) VEPsc) BAEPs a) abnormal in 5 patients (focal temporal epileptic activity in 2, occipital in 1, and left hemisphere in 1; generalized in 1)b) abnormal in 7 patients (marked and bilateral in 2)c) abnormal in 1 patient (sensorineural hearing loss) EEG improved in 3 out of 4 patients on GFD and antiepileptic drugs Increased risk of neurological abnormalities in atypical and silent forms that involves older ages and older ages at the diagnosis
Pennisi et al., 2017 a) 20 de novo CD patientsb) 20 CD patients on GFD a) 4 M/16 Fb) 6 M/14 F a) Mean 35.00 ± 12.03 (SD)b) Mean 35.10 ± 6.02 (SD) a) Dysthymic disorder (5 patients); higher score for depression, anxiety, and irritabilityb) Normal TMS - Shorter CSP in de novo patients than GFD patients- Smaller motor response amplitude in all patients- Reduced ICI and enhanced ICF in all patients- Increased ICF in gluten-restricted compared to non-restricted patients A prolonged dietary regimen induced a recover of most but not all electrocortical changes Subtle intracortical synaptic dysfunction may persist notwithstanding the GFD

BAEPs, brainstem auditory evoked potentials; CD, Celiac disease; CSP, cortical silent period; EEG, electroencephalography; F, female; GFD, gluten-free diet; ICF, intracortical facilitation; ICI, intracortical inhibition; M, male; OSA, obstructive sleep apnea; PLEDs, Periodic Lateralized Epileptiform Discharges; rMT, resting motor threshold; SD, standard deviation; SEPs, somatosensory evoked potentials; TMS, transcranial magnetic stimulation; VEMPs, vestibular evoked myogenic potentials; VEPs, visual evoked potentials.

Summary figure illustrating the main neurophysiological findings in patients with celiac disease. BAEPs, brainstem auditory evoked potentials; EEG, electroencephalography. GFD, gluten-free diet; SEPs, somatosensory evoked potentials; TMS, Transcranial magnetic stimulation; VEPs, visual evoked potentials.

From a pure neurophysiological perspective, findings from EEG, SEPs, and TMS seem to converge on an overall profile of “hyperexcitable celiac brain,” albeit this may not be confined to the cerebral cortex. Indeed, an increase in cerebral cortical excitability may arise from enhanced inputs from the cerebellum (Tijssen et al., 2000). In this context, it is important to remember that malabsorption syndrome (with the consequent deficiency of vitamins and other nutrients) probably does not account for these cortical manifestations, given that it takes place in the most severely affected patients whose intestinal mucosa are seriously damaged and do not recover after institution of a GFD (Pennisi et al., 2014).

Regarding humoral autoimmunity to neuronal antigens, deposits of anti-tTG2 and anti-tTG6 antibodies have been found not only in the small intestine but also in different CNS sites (cerebellum, pons, medulla, brain blood vessels) (Hadjivassiliou et al., 2008). Furthermore, a possible BBB lesion, secondary to diffuse infiltration of T-lymphocytes and inflammatory cells within the perivascular cuffing might expose cerebral tissues to antibodies (Hadjivassiliou et al., 2010). The result may be a vicious circle that eventually leads to a prevailing synaptic hyperexcitation and a weaker inhibition at the cortical level (Pennisi et al., 2014). The increased excitability may also be the correlate of a glutamate-induced cortical rearrangement or a dysfunctional control of GABAergic inhibitory interneurons. In particular, because glutamate is of pivotal importance in synaptic plasticity, it can be speculated that immune system dysregulation triggered by gluten ingestion, might result in a long-standing activation of post-synaptic glutamate receptors accounting for the enhanced hyperexcitability (Bella et al., 2015).

The neurophysiological-based approach to CD should take into account potential pitfalls and critical aspects related to both the techniques themselves and methodological biases in the studies reviewed here. First, as mentioned, electrophysiological changes are not disease-specific. Second, an association finding does not mean causative relationship. For instance, an association between CD and amyotrophic lateral sclerosis was previously reported in different investigations (Turner et al., 2007, 2013; Brown et al., 2010; Bersano et al., 2015; Gadoth et al., 2015) but not confirmed in a large population-based cohort study (Ludvigsson et al., 2014). Finally, it is mandatory to make a differential diagnosis between hyperexcitability-related seizures and incidental EEG findings in neurologically asymptomatic CD subjects. In the latter case, EEG changes represent a confounding factor and a long follow-up is required (Parisi et al., 2014).

The response of neurological symptoms to a GFD is still controversial. Current knowledge encompasses an initial phase when patients are “gluten-sensitive” and a subsequent stage characterized by “gluten-insensitivity” (Tursi et al., 2006). An older age at diagnosis or a prolonged period of gluten ingestion may account for persistent neurological symptoms after a relatively short period of GFD (Bella et al., 2015). Moreover, gluten restriction is not usually effective in patients with refractory CD and in those with an associated autoimmune disease or some neurological complications (Hadjivassiliou et al., 2010; Castillo et al., 2015; Campagna et al., 2017). It is reasonable to conclude that some neurological aspects improve after diet restriction whereas others persist, supporting the concept that the more prolonged the GFD, the more likely clinical and neurophysiological remission may occur. However, given that neurological impairment may develop despite an adequate adherence to a GFD (Luostarinen et al., 2003; Chin and Latov, 2005; Tursi et al., 2006; Bürk et al., 2009), other causative factors have to contribute (McKeon et al., 2014): (a) accidental minimal gluten contamination despite a good dietary compliance (Green and Jabri, 2003); (b) direct gliadin-mediated inflammatory attack; (c) other components that are independent of GFD (Tijssen et al., 2000).

Based on further understanding of the pathogenesis and treatment of CD, neurophysiology-targeted non-dietary therapies are in development (Schuppan et al., 2009). Similarly, modern rehabilitation approach involves organizational measures that promote not only clinical recovery but also a better quality of life (Sabel'nikova et al., 2013) through the support of different medical and non-medical specialists (Usanova et al., 2012).

In conclusion, neurophysiology, together with clinical, serological, and imaging data, can help in disentangling the multifaceted physiopathological and neurobiological mechanisms coupling gut and brain in CD. The eventual identification of neurophysiological markers might be useful in the diagnosis and monitoring of CD, aiming to improve the healthcare of both single subjects and the global community.

 Author contributions

All authors provided substantial contributions to the conception, drafting, critical revision for important intellectual content, final approval, and agreement to be accountable for all aspects of the work. In particular, MP and AB conceived and designed the study, MC and GL reviewed the literature and drafted the manuscript, and GP and RB critically reviewed and finalized the paper.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We would like to thank Charlesworth Author Services (http://www.charlesworthauthorservices.com) for English language editing.

 References Abenavoli L. (2010). Nervous system in the gluten syndrome: a close relationship. Med. Hypotheses 74, 204–205. 10.1016/j.mehy.2009.08.01219744798 Addolorato G. Capristo E. Ghittoni G. Valeri C. Mascianà R. Ancona C. . (2001). Anxiety but not depression decreases in coeliac patients after one-year gluten-free diet: a longitudinal study. Scand. J. Gastroenterol. 36, 502–506. 10.1080/0036552011975411346203 Aksoy E. Tıraş-Teber S. Kansu A. Deda G. Kartal A. (2016). Neurological findings spectrum in Celiac disease. Turk. J. Pediatr. 58, 233–240. 10.24953/turkjped.2016.03.00128266186 Alaedini A. Green P. H. (2008). Autoantibodies in celiac disease. Autoimmunity 41, 19–26. 10.1080/0891693070161921918176861 Barcia G. Posar A. Santucci M. Parmeggiani A. (2008). Autism and coeliac disease. J. Autism Dev. Disord. 38, 407–408. 10.1007/s10803-007-0480-317985220 Bella R. Cantone M. Lanza G. Ferri R. Vinciguerra L. Puglisi V. . (2016). Cholinergic circuitry functioning in patients with vascular cognitive impairment–no dementia. Brain Stimul. 9, 225–233. 10.1016/j.brs.2015.09.01326515786 Bella R. Ferri R. Cantone M. Pennisi M. Lanza G. Malaguarnera G. . (2011a). Motor cortex excitability in vascular depression. Int. J. Psychophysiol. 82, 248–253. 10.1016/j.ijpsycho.2011.09.00621945481 Bella R. Ferri R. Lanza G. Cantone M. Pennisi M. Puglisi V. . (2013). TMS follow-up study in patients with vascular cognitive impairment-no dementia. Neurosci. Lett. 534, 155–159. 10.1016/j.neulet.2012.12.01723274709 Bella R. Ferri R. Pennisi M. Cantone M. Lanza G. Malaguarnera G. . (2011b). Enhanced motor cortex facilitation in patients with vascular cognitive impairment-no dementia. Neurosci. Lett. 503, 171–175. 10.1016/j.neulet.2011.08.02221875648 Bella R. Lanza G. Cantone M. Giuffrida S. Puglisi V. Vinciguerra L. . (2015). Effect of a gluten-free diet on cortical excitability in adults with Celiac disease. PLoS ONE 10:e0129218. 10.1371/journal.pone.012921826053324 Bersano E. Stecco A. D'Alfonso S. Corrado L. Sarnelli M. F. Solara V. . (2015). Coeliac disease mimicking amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 277–279. 10.3109/21678421.2014.98061425646867 Bhatia K. P. Brown P. Gregory R. Lennox G. G. Manji H. Thompson P. D. . (1995). Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 118, 1087–1093. 10.1093/brain/118.5.10877496772 Bingley P. J. Williams A. J. Norcross A. J. Unsworth D. J. Lock R. J. Ness A. R. . (2004). Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ 328, 322–323. 10.1136/bmj.328.7435.32214764493 Bordet R. Ihl R. Korczyn A. D. Lanza G. Jansa J. Hoerr R. . (2017). Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report. BMC Med. 15:107. 10.1186/s12916-017-0869-628539119 Borg M. (2006). Symptomatic myoclonus. Neurophysiol. Clin. 36, 309–318. 10.1016/j.neucli.2006.12.00617336775 Briani C. Zara G. Alaedini A. Grassivaro F. Ruggero S. Toffanin E. . (2008). Neurological complications of celiac disease and autoimmune mechanisms: a prospective study. J. Neuroimmunol. 195, 171–175. 10.1016/j.jneuroim.2008.01.00818343508 Brown K. J. Jewells V. Herfarth H. Castillo M. (2010). White matter lesions suggestive of amyotrophic lateral sclerosis attributed to celiac disease. Am. J. Neuroradiol. 31, 880–881. 10.3174/ajnr.A182619910450 Bürk K. Bösch S. Müller C. A. Melms A. Zühlke C. Stern M. . (2001). Sporadic cerebellar ataxia associated with gluten sensitivity. Brain 124, 1013–1019. 10.1093/brain/124.5.101311335703 Bürk K. Farecki M. L. Lamprecht G. Roth G. Decker P. Weller M. . (2009). Neurological symptoms in patients with biopsy proven celiac disease. Mov. Disord. 24, 2358–2362. 10.1002/mds.2282119845007 Bushara K. O. (2005). Neurologic presentation of celiac disease. Gastroenterology 128, S92–S97. 10.1053/j.gastro.2005.02.01815825133 Cakir D. Tosun A. Polat M. Celebisoy N. Gokben S. Aydogdu S. . (2007). Subclinical neurological abnormalities in children with celiac disease receiving a gluten-free diet. J. Pediatr. Gastroenterol. Nutr. 45, 366–369. 10.1097/MPG.0b013e31806907e817873753 Campagna G. Pesce M. Tatangelo R. Rizzuto A. La Fratta I. Grilli A. (2017). The progression of coeliac disease: its neurological and psychiatric implications. Nutr. Res. Rev. 30, 25–35. 10.1017/S095442241600021427976606 Canales P. Mery V. P. Larrondo F. J. Bravo F. L. Godoy J. (2006). Epilepsy and celiac disease: favorable outcome with a gluten-free diet in a patient refractory to antiepileptic drugs. Neurologist 12, 318–321. 10.1097/01.nrl.0000250950.35887.6c17122729 Cantone M. Bramanti A. Lanza G. Pennisi M. Bramanti P. Pennisi G. . (2017). Cortical plasticity in depression. ASN Neuro 9:1759091417711512. 10.1177/175909141771151228629225 Cantone M. Di Pino G. Capone F. Piombo M. Chiarello D. Cheeran B. . (2014). The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia. Clin. Neurophysiol. 125, 1509–1532. 10.1016/j.clinph.2014.04.01024840904 Carta M. G. Conti A. Lecca F. Sancassiani F. Cossu G. Carruxi R. . (2015). The burden of depressive and bipolar disorders in Celiac disease. Clin. Pract. Epidemiol. Ment. Health 11, 180–185. 10.2174/174501790151101018026962323 Carta M. G. Hardoy M. C. Boi M. F. Mariotti S. Carpiniello B. Usai P. (2002). Association between panic disorder, major depressive disorder and celiac disease: a possible role of thyroid autoimmunity. J. Psychosom. Res. 53, 789–793. 10.1016/S0022-3999(02)00328-812217453 Carta M. G. Hardoy M. C. Usai P. Carpiniello B. Angst J. (2003). Recurrent brief depression in celiac disease. J. Psychosom. Res. 55, 573–574. 10.1016/S0022-3999(03)00547-614642990 Casciato S. Morano A. Albini M. Fanella M. Lapenta L. Fattouch J. . (2015). Cryptogenic focal epilepsy and “hidden” celiac disease in adulthood: a causal or accidental link? Int. J. Neurosci. 125, 913–917. 10.3109/00207454.2014.98322722484003 Casella S. Zanini B. Lanzarotto F. Ricci C. Marengoni A. Romanelli G. . (2012). Cognitive performance is impaired in coeliac patients on gluten free diet: a case-control study in patients older than 65 years of age. Dig. Liver Dis. 44, 729–735. 10.1016/j.dld.2012.03.00822484003 Castillo N. E. Theethira T. G. Leffler D. A. (2015). The present and the future in the diagnosis and management of celiac disease. Gastroenterol Rep (Oxf) 3, 3–11. 10.1093/gastro/gou06525326000 Chin R. L. Latov N. (2005). Peripheral neuropathy and Celiac disease. Curr. Treat. Options Neurol. 7, 43–48. 10.1007/s11940-005-0005-315610706 Chin R. L. Sander H. W. Brannagan T. H. Green P. H. Hays A. P. Alaedini A. . (2003). Celiac neuropathy. Neurology 60, 1581–1585. 10.1212/01.WNL.0000063307.84039.C712771245 Cicarelli G. Della Rocca G. Amboni M. Ciacci C. Mazzacca G. Filla A. . (2003). Clinical and neurological abnormalities in adult celiac disease. Neurol. Sci. 24, 311–317. 10.1007/s10072-003-0181-414716525 Collin P. Pirttilä T. Nurmikko T. Somer H. Erilä T. Keyriläinen O. (1991). Celiac disease, brain atrophy, and dementia. Neurology 41, 372–375. 10.1212/WNL.41.3.3722006004 Concerto C. Lanza G. Cantone M. Ferri R. Pennisi G. Bella R. . (2015). Repetitive transcranial magnetic stimulation in patients with drug-resistant major depression: a six-month clinical follow-up study. Int. J. Psychiatry Clin. Pract. 19, 252–258. 10.3109/13651501.2015.108432926398527 Concerto C. Lanza G. Cantone M. Pennisi M. Giordano D. Spampinato C. . (2013). Different patterns of cortical excitability in major depression and vascular depression: a transcranial magnetic stimulation study. BMC Psychiatry 13:300. 10.1186/1471-244X-13-30024206945 Cooke W. T. Smith W. T. (1966). Neurological disorders associated with adult coeliac disease. Brain 89, 683–722. 10.1093/brain/89.4.6834163580 Dai A. I. Akcali A. Varan C. Demiryürek A. T. (2014). Prevalence of resistant occipital lobe epilepsy associated with celiac disease in children. Childs. Nerv. Syst. 30, 1091–1098. 10.1007/s00381-014-2387-624566676 Deconinck N. Scaillon M. Segers V. Groswasser J. J. Dan B. (2006). Opsoclonus-myoclonus associated with celiac disease. Pediatr. Neurol. 34, 312–314. 10.1016/j.pediatrneurol.2005.08.03416638509 De Santis A. Addolorato G. Romito A. Caputo S. Giordano A. Gambassi G. . (1997). Schizophrenic symptoms and SPECT abnormalities in a coeliac patient: regression after a gluten-free diet. J. Intern. Med. 242, 421–423. 10.1046/j.1365-2796.1997.00200.x9408073 Di Lazzaro V. Pilato F. Batocchi A. P. Restuccia D. Cammarota G. Profice P. (2010). Tired legs–a gut diagnosis. Lancet 376, 1798. 10.1016/S0140-6736(10)61163-421093652 Fung V. S. Duggins A. Morris J. G. Lorentz I. T. (2000). Progressive myoclonic ataxia associated with celiac disease presenting as unilateral cortical tremor and dystonia. Mov. Disord. 15, 732–734. 10.1002/1531-8257(200007)15:4<732::AID-MDS1021>3.0.CO;2-J10928587 Freeman H. J. (2008). Neurological disorders in adult celiac disease. Can. J. Gastroenterol. 22, 909–911. 10.1155/2008/82463119018335 Gadoth A. Nefussy B. Bleiberg M. Klein T. Artman I. Drory V. E. (2015). Transglutaminase 6 antibodies in the serum of patients with amyotrophic lateral sclerosis. JAMA Neurol. 72, 676–681. 10.1001/jamaneurol.2015.4825867286 Gobbi G. Bouquet F. Greco L. Lambertini A. Tassinari C. A. Ventura A. . (1992). Coeliac disease, epilepsy, and cerebral calcifications. the Italian working group on coeliac disease and epilepsy. Lancet 340, 439–443. 10.1016/0140-6736(92)91766-21354781 Green P. H. Alaedini A. Sander H. W. Brannagan T. H. III. Latov N. Chin R. L. (2005). Mechanisms underlying celiac disease and its neurologic manifestations. Cell. Mol. Life Sci. 62, 791–799. 10.1007/s00018-004-4109-915868404 Green P. H. Jabri B. (2003). Coeliac disease. Lancet 362, 383–391. 10.1016/S0140-6736(03)14027-512907013 Hadjivassiliou M. Aeschlimann P. Strigun A. Sanders D. S. Woodroofe N. Aeschlimann D. (2008). Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann. Neurol. 64, 332–343. 10.1002/ana.2145018825674 Hadjivassiliou M. Grünewald R. A. Davies-Jones G. A. (2002a). Gluten sensitivity as a neurological illness. J. Neurol. Neurosurg. Psychiatr. 72, 560–563. 10.1136/jnnp.72.5.56011971034 Hadjivassiliou M. Boscolo S. Davies-Jones G. A. Grünewald R. A. Not T. Sanders D. S. . (2002b). The humoral response in the pathogenesis of gluten ataxia. Neurology 58, 1221–1226. 10.1212/WNL.58.8.122111971090 Hadjivassiliou M. Duker A. P. Sanders D. S. (2014). Gluten-related neurologic dysfunction. Handb. Clin. Neurol. 120, 607–619. 10.1016/B978-0-7020-4087-0.00041-324365341 Hadjivassiliou M. Grünewald R. A. Chattopadhyay A. K. Davies-Jones G. A. Gibson A. Jarratt J. A. . (1998). Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 352, 1582–1585. 10.1016/S0140-6736(98)05342-29843103 Hadjivassiliou M. Grünewald R. A. Lawden M. Davies-Jones G. A. Powell T. Smith C. M. (2001). Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology 56, 385–388. 10.1212/WNL.56.3.38511171906 Hadjivassiliou M. Mäki M. Sanders D. S. Williamson C. A. Grünewald R. A. Woodroofe N. M. . (2006). Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 66, 373–377. 10.1212/01.wnl.0000196480.55601.3a16476935 Hadjivassiliou M. Sanders D. D. Aeschlimann D. P. (2015). Gluten-related disorders: gluten ataxia. Dig. Dis. 33, 264–268. 10.1159/00036950925925933 Hadjivassiliou M. Sanders D. S. Grünewald R. A. Woodroofe N. Boscolo S. Aeschlimann D. (2010). Gluten sensitivity: from gut to brain. Lancet Neurol. 9, 318–330. 10.1016/S1474-4422(09)70290-X20170845 Hallert C. Aström J. Sedvall G. (1982). Psychic disturbances in adult coeliac disease. III. Reduced central monoamine metabolism and signs of depression. Scand J. Gastroenterol. 17, 25–28. 10.3109/003655282091810396182605 Hanagasi H. A. Gürol E. Sahin H. A. Emre M. (2001). Atypical neurological involvement associated with celiac disease. Eur. J. Neurol. 8, 67–69. 10.1046/j.1468-1331.2001.00155.x11509083 Hernanz A. Polanco I. (1991). Plasma precursor amino acids of central nervous system monoamines in children with coeliac disease. Gut 32, 1478–1481. 10.1136/gut.32.12.14781773952 Holmes G. K. (1996). Non-malignant complications of coeliac disease. Acta Paediatr. Suppl. 412, 68–75. 10.1111/j.1651-2227.1996.tb14257.x8783765 Holmes G. K. (2002). Coeliac disease and malignancy. Dig. Liver Dis. 34, 229–237. 10.1016/S1590-8658(02)80198-011990397 Hu W. T. Murray J. A. Greenaway M. C. Parisi J. E. Josephs K. A. (2006). Cognitive impairment and celiac disease. Arch. Neurol. 63, 1440–1446. 10.1001/archneur.63.10.144017030661 Işıkay S. Kocamaz H. Sezer S. Özkars M. Y. Işıkay N. Filik B. . (2015a). The frequency of epileptiform discharges in Celiac disease. Pediatr. Neurol. 53, 78–82. 10.1016/j.pediatrneurol.2015.02.00626092417 Işıkay S. Hizli Ş. Çoşkun S. Yilmaz K. (2015b). Increased tissue transglutaminase levels are associated with increased epileptiform activity in electroencephalography among patients with celiac disease. Arq. Gastroenterol. 52, 272–277. 10.1590/S0004-2803201500040000526840467 Javed S. Safdar A. Forster A. Selvan A. Chadwick D. Nicholson A. . (2012). Refractory coeliac disease associated with late onset epilepsy, ataxia, tremor and progressive myoclonus with giant cortical evoked potentials–a case report and review of literature. Seizure 21, 482–485. 10.1016/j.seizure.2012.04.00322565067 Kaplan J. G. Pack D. Horoupian D. DeSouza T. Brin M. Schaumburg H. (1988). Distal axonopathy associated with chronic gluten enteropathy: a treatable disorder. Neurology 38, 642–645. 10.1212/WNL.38.4.6422832786 Karwautz A. Wagner G. Berger G. Sinnreich U. Grylli V. Huber W. D. (2008). Eating pathology in adolescents with celiac disease. Psychosomatics 49, 399–406. 10.1176/appi.psy.49.5.39918794508 Labate A. Gambardella A. Messina D. Tammaro S. Le Piane E. Pirritano D. . (2001). Silent celiac disease in patients with childhood localization-related epilepsies. Epilepsia 42, 1153–1155. 10.1046/j.1528-1157.2001.45700.x11580763 Lanza G. Bachmann C. G. Ghorayeb I. Wang Y. Ferri R. Paulus W. (2017a). Central and peripheral nervous system excitability in restless legs syndrome. Sleep Med. 31, 49–60. 10.1016/j.sleep.2016.05.01027745789 Lanza G. Bella R. Giuffrida S. Cantone M. Pennisi G. Spampinato C. . (2013). Preserved transcallosal inhibition to transcranial magnetic stimulation in nondemented elderly patients with leukoaraiosis. Biomed Res. Int. 2013:351680. 10.1155/2013/35168023984349 Lanza G. Bramanti P. Cantone M. Pennisi M. Pennisi G. Bella R. (2017b). Vascular cognitive impairment through the looking glass of transcranial magnetic stimulation. Behav. Neurol. 2017:1421326. 10.1155/2017/142132628348458 Lanza G. Cantone M. Lanuzza B. Pennisi M. Bella R. Pennisi G. . (2015a). Distinctive patterns of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome, restless legs syndrome, insomnia, and sleep deprivation. Sleep Med. Rev. 19, 39–50. 10.1016/j.smrv.2014.04.00124849846 Lanza G. Lanuzza B. Aricò D. Cantone M. Cosentino F. I. Pennisi M. . (2015b). Direct comparison of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome and restless legs syndrome. Sleep Med. 16, 138–142. 10.1016/j.sleep.2014.08.01625534710 Lebwohl B. Sanders D. S. Green P. H. R. (2017). Coeliac disease. Lancet [Epub ahead of print]. 10.1016/S0140-6736(17)31796-8 Licchetta L. Bisulli F. Di Vito L. La Morgia C. Naldi I. Volta U. . (2011). Epilepsy in coeliac disease: not just a matter of calcifications. Neurol. Sci. 32, 1069–1074. 10.1007/s10072-011-0629-x21630037 Lichtwark I. T. Newnham E. D. Shepherd S. J. Hosking P. Gibson P. R. . (2014). Cognitive impairment in coeliac disease improves on a gluten-free diet and correlates with histological and serological indices of disease severity. Aliment. Pharmacol. Ther. 40, 160–170. 10.1111/apt.1280924889390 Lionetti E. Francavilla R. Pavone P. Pavone L. Francavilla T. Pulvirenti A. . (2010). The neurology of coeliac disease in childhood: what is the evidence? A systematic review and meta-analysis. Dev. Med. Child Neurol. 52, 700–707. 10.1111/j.1469-8749.2010.03647.x20345955 Lu C. S. Thompson P. D. Quinn N. P. Parkes J. D. Marsden C. D. (1986). Ramsay Hunt syndrome and coeliac disease: a new association? Mov. Disord. 1, 209–219. 10.1002/mds.8700103063504245 Ludvigsson J. F. Mariosa D. Lebwohl B. Fang F. (2014). No association between biopsy-verified celiac disease and subsequent amyotrophic lateral sclerosis–a population-based cohort study. Eur. J. Neurol. 21, 976–982. 10.1111/ene.1241924708265 Ludvigsson J. F. Zingone F. Tomson T. Ekbom A. Ciacci C. (2012). Increased risk of epilepsy in biopsy-verified celiac disease: a population-based cohort study. Neurology 78, 1401–1407. 10.1212/WNL.0b013e318254472822517096 Luostarinen L. Himanen S. L. Luostarinen M. Collin P. Pirttilä T. (2003). Neuromuscular and sensory disturbances in patients with well treated coeliac disease. J. Neurol. Neurosurg. Psychiatr. 74, 490–494. 10.1136/jnnp.74.4.49012640070 Lurie Y. Landau D. A. Pfeffer J. Oren R. (2008). Celiac disease diagnosed in the elderly. J. Clin. Gastroenterol. 42, 59–61. 10.1097/01.mcg.0000247995.12087.7b18097291 Magaudda A. Dalla Bernardina B. De Marco P. Sfaello Z. Longo M. Colamaria V. . (1993). Bilateral occipital calcification, epilepsy and coeliac disease: clinical and neuroimaging features of a new syndrome. J. Neurol. Neurosurg. Psychiatr. 56, 885–889. 10.1136/jnnp.56.8.8858350105 McKeon A. Lennon V. A. Pittock S. J. Kryzer T. J. Murray J. (2014). The neurologic significance of celiac disease biomarkers. Neurology 83, 1789–1796. 10.1212/WNL.000000000000097025261501 Morello F. Ronzani G. Cappellari F. (2003). Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease. Neurol. Sci. 24, 85–89. 12827546 Mumford C. J. Fletcher N. A. Ironside J. W. Warlow C. P. (1996). Progressive ataxia, focal seizures, and malabsorption syndrome in a 41 year old woman. J. Neurol. Neurosurg. Psychiatr. 60, 225–230. 10.1136/jnnp.60.2.2258708663 Niederhofer H. Pittschieler K. (2006). A preliminary investigation of ADHD symptoms in persons with celiac disease. J. Atten. Disord. 10, 200–204. 10.1177/108705470629210917085630 Nikpour S. (2012). Neurological manifestations, diagnosis, and treatment of celiac disease: a comprehensive review. Iran J. Neurol. 11, 59–64. 24250863 Parisi P. Pietropaoli N. Ferretti A. Nenna R. Mastrogiorgio G. Del Pozzo M. . (2015). Role of the gluten-free diet on neurological-EEG findings and sleep disordered breathing in children with celiac disease. Seizure 25, 181–183. 10.1016/j.seizure.2014.09.01625457448 Parisi P. Principessa L. Ferretti A. D'Onofrio D. Del Giudice E. Pacchiarotti C. . (2014). “EEG abnormalities” may represent a confounding factor in celiac disease: a 4-year follow-up family report. Epilepsy Behav. Case Rep. 2, 40–42. 10.1016/j.ebcr.2014.01.00825667866 Paulus W. Classen J. Cohen L. G. Large C. H. Di Lazzaro V. Nitsche M. . (2008). State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul. 1, 151–163. 10.1016/j.brs.2008.06.00220633382 Pawlak-Osińska K. Kaźmierczak H. Kuczyńska R. Szaflarska-Popławska A. (2007). Looking for the auditory and vestibular pathology in celiac disease. Otolaryngol. Pol. 61, 178–183. 10.1016/S0030-6657(07)70409-217668806 Pellecchia M. T. Scala R. Perretti A. De Michele G. Santoro L. Filla A. . (1999). Cerebellar ataxia associated with subclinical celiac disease responding to gluten-free diet. Neurology 53, 1606–1608. 10.1212/WNL.53.7.1606-a10534283 Pennisi G. Bella R. Lanza G. (2015). Motor cortex plasticity in subcortical ischemic vascular dementia: what can TMS say? Clin. Neurophysiol. 126, 851–852. 10.1016/j.clinph.2014.09.00125270240 Pennisi G. Ferri R. Cantone M. Lanza G. Pennisi M. Vinciguerra L. . (2011a). A review of transcranial magnetic stimulation in vascular dementia. Dement. Geriatr. Cogn. Disord. 31, 71–80. 10.1159/00032279821242688 Pennisi G. Ferri R. Lanza G. Cantone M. Pennisi M. Puglisi V. . (2011b). Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability. J. Neural. Transm. (Vienna) 118, 587–598. 10.1007/s00702-010-0554-921207079 Pennisi G. Lanza G. Giuffrida S. Vinciguerra L. Puglisi V. Cantone M. . (2014). Excitability of the motor cortex in de novo patients with celiac disease. PLoS ONE 9:e102790. 10.1371/journal.pone.010279025062250 Pennisi M. Lanza G. Cantone M. Ricceri R. Ferri R. D'Agate C. C. . (2017). Cortical involvement in celiac disease before and after long-term gluten-free diet: a transcranial magnetic stimulation study. PLoS ONE 12:e0177560. 10.1371/journal.pone.017756028489931 Pennisi M. Lanza G. Cantone M. Ricceri R. Spampinato C. Pennisi G. . (2016). Correlation between motor cortex excitability changes and cognitive impairment in vascular depression: pathophysiological insights from a longitudinal TMS study. Neural Plast. 2016:8154969. 10.1155/2016/815496927525127 Pratesi R. Modelli I. C. Martins R. C. Almeida P. L. Gandolfi L. (2003). Celiac disease and epilepsy: favorable outcome in a child with difficult to control seizures. Acta Neurol. Scand. 108, 290–293. 10.1034/j.1600-0404.2003.00082.x12956865 Ranua J. Luoma K. Auvinen A. Mäki M. Haapala A. M. Peltola J. . (2005). Celiac disease-related antibodies in an epilepsy cohort and matched reference population. Epilepsy Behav. 6, 388–392. 10.1016/j.yebeh.2005.01.00715820348 Sabel'nikova E. A. Krums L. M. Parfenov A. I. Vorob'eva N. N. Gudkova R. B. (2013). Specific features of rehabilitation in patients with gluten-sensitivity celiac disease. Ter. Arkh. 85, 42–47. 23536945 Sallem F. S. Castro L. M. Jorge C. Marchiori P. Barbosa E. (2009). Gluten sensitivity presenting as myoclonic epilepsy with cerebellar syndrome. Mov. Disord. 24, 2162–2163. 10.1002/mds.2257619705357 Sarrigiannis P. G. Hoggard N. Aeschlimann D. Sanders D. S. Grünewald R. A. Unwin Z. C. . (2014). Myoclonus ataxia and refractory coeliac disease. Cerebellum Ataxia 1:11. 10.1186/2053-8871-1-1126331035 Schuppan D. Junker Y. Barisani D. (2009). Celiac disease: from pathogenesis to novel therapies. Gastroenterology 137, 1912–1933. 10.1053/j.gastro.2009.09.00819766641 Siqueira Neto J. I. Costa A. C. Magalhães F. G. Silva G. S. (2004). Neurological manifestations of celiac disease. Arq. Neuropsiquiatr. 62, 969–972. 10.1590/S0004-282X200400060000715608953 Spampinato C. Aguglia E. Concerto C. Pennisi M. Lanza G. Bella R. . (2013). Transcranial magnetic stimulation in the assessment of motor cortex excitability and treatment of drug-resistant major depression. IEEE Trans. Neural Syst. Rehabil. Eng. 21, 391–403. 10.1109/TNSRE.2013.225643223559064 Tijssen M. A. Thom M. Ellison D. W. Wilkins P. Barnes D. Thompson P. D. . (2000). Cortical myoclonus and cerebellar pathology. Neurology 54, 1350–1356. 10.1212/WNL.54.6.135010746609 Tison F. Arne P. Henry P. (1989). Myoclonus and adult coeliac disease. J. Neurol. 236, 307–308. 10.1007/BF003144642760650 Turner M. R. Chohan G. Quaghebeur G. Greenhall R. C. Hadjivassiliou M. Talbot K. (2007). A case of celiac disease mimicking amyotrophic lateral sclerosis. Nat. Clin. Pract. Neurol. 3, 581–584. 10.1038/ncpneuro063117914346 Turner M. R. Goldacre R. Ramagopalan S. Talbot K. Goldacre M. J. (2013). Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology 81, 1222–1225. 10.1212/WNL.0b013e3182a6cc1323946298 Tursi A. Giorgetti G. M. Iani C. Arciprete F. Brandimarte G. Capria A. . (2006). Peripheral neurological disturbances, autonomic dysfunction, and antineuronal antibodies in adult celiac disease before and after a gluten-free diet. Dig. Dis. Sci. 51, 1869–1874. 10.1007/s10620-005-9054-416967315 Usai P. Serra A. Marini B. Mariotti S. Satta L. Boi M. F. . (2004). Frontal cortical perfusion abnormalities related to gluten intake and associated autoimmune disease in adult coeliac disease: 99mTc-ECD brain SPECT study. Dig. Liver Dis. 36, 513–518. 10.1016/j.dld.2004.03.01015334770 Usanova E. P. Shapkina O. A. Matkivskiǐ R. A. Fedulova É. N. Uspenskaia I. D. (2012). The organization of comprehensive rehabilitation of the children presenting with inflammatory intestinal diseases and celiacia under the conditions of a health resort. Vopr. Kurortol. Fizioter. Lech. Fiz. Kult. 4, 37–40. Uygur-Bayramicli O. Ozel A. M. (2011). Celiac disease is associated with neurological syndromes. Dig. Dis. Sci. 56, 1587–1588. 10.1007/s10620-011-1663-521409373 van Hees N. J. Van der Does W. Giltay E. J. (2013). Coeliac disease, diet adherence and depressive symptoms. J. Psychosom. Res. 74, 155–160. 10.1016/j.jpsychores.2012.11.00723332531 Vieira C. Jatobá I. Matos M. Diniz-Santos D. Silva L. R. (2013). Prevalence of celiac disease in children with epilepsy. Arq. Gastroenterol. 50, 290–296. 10.1590/S0004-2803201300040001024474232 Yelland G. W. (2017). Gluten-induced cognitive impairment (“brain fog”) in coeliac disease. J. Gastroenterol. Hepatol. 32, 90–93. 10.1111/jgh.1370628244662 Zelnik N. Pacht A. Obeid R. Lerner A. (2004). Range of neurologic disorders in patients with celiac disease. Pediatrics 113, 1672–1676. 10.1542/peds.113.6.167215173490 Ziemann U. Reis J. Schwenkreis P. Rosanova M. Strafella A. Badawy R. . (2015). TMS and drugs revisited 2014. Clin. Neurophysiol. 126, 1847–1868. 10.1016/j.clinph.2014.08.02825534482 Zingone F. Siniscalchi M. Capone P. Tortora R. Andreozzi P. Capone E. . (2010). The quality of sleep in patients with coeliac disease. Aliment. Pharmacol. Ther. 32, 1031–1036. 10.1111/j.1365-2036.2010.04432.x20937049